Health
Takeda, Eli Lilly Must Defend Racketeering Suit Over Diabetes Drug, Judge Rules
Takeda Pharmaceutical Co.'s Actos diabetes medication.
Photographer: JB Reed/Bloomberg
This article is for subscribers only.
A federal judge ruled Takeda Pharmaceutical Co. and Eli Lilly & Co. must defend a racketeering lawsuit claiming they defrauded third-party payers by marketing the Actos diabetes drug without disclosing its association with the risk of bladder cancer.
US District Judge John Holcomb certified a class-action case for thousands of third-party payers who reimbursed for Actos between 1999 and 2010, according to the May 24 opinion unsealed Monday in federal court in Santa Ana, California. Holcomb appointed Painters and Allied Trades District Council 82 Health Care Fund as the class representative.